Guidance shifted from reiterating 2025 revenues above $190 million and adjusted EBITDA above $50 million to projecting 2026 revenues above $190 million and adjusted EBITDA greater than $38 million, ...

(NASDAQ:BTMD) used its fourth-quarter and full-year 2025 earnings call to outline changes made over the past year to its commercial organization and operating model, while also detailing near-term ...

Corp. undertakes no obligation to update them in the future. Therefore, statements should not be relied upon as representing the company's views as of any subsequent date. For discussion of risks and ...

Biote Corp (BTMD) focuses on expanding its sales force and enhancing technology, despite facing revenue and margin pressures.

Reports Q3 revenue $51.4M, consensus $51.4M. “Biote’s (BTMD) third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to ...

Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. I would now like to turn the conference over ...

Biote CEO Terry Weber moved to Dallas from Orange County, Calif., in 2018 to lead the hormone replacement therapy provider into its next stage of growth. The Irving-based company is expecting up to ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...